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medical records including disease characteristics, treatment regimens, medications 
used and treatment outcomes. The study was conducted from the perspective of a 
Macao public hospital. The European Organization for Research and Treatment of 
Cancer quality-of-life questionnaire (EORTC QLQ-C30) (version 3.0, Chinese-Hong 
Kong) was used for the HRQoL assessment. RESULTS: The standard-dose melphalan-
based and vincristine-doxorubicin-dexamethasone-based regimens (VAD) were the 
most common treatment regimens. There were 24 and 10 patients in the melphalan-
based and VAD-based group respectively. Six patients were not studied due to incom-
plete data. Patients in the melphalan-based group were at a more advanced age (70.4 
± 7.4 years; p < 0.001). The melphalan-based group showed a lower overall treatment 
cost (MOP 29,231 versus MOP 44,831; p = 0.521, 1 USD = 8 MOP), especially on 
inpatient medication cost (MOP 5,809 versus MOP 13,908; p = 0.096). The VAD-
based group showed better clinical outcomes than the melphalan-based group in terms 
of overall survival, progression-free survival and survival probability with time. The 
incremental cost-effectiveness ratio of VAD-based regimens compared with melpha-
lan-based regimens was MOP 6,695 per life-year-gained. CONCLUSIONS: The 
results of this study suggest that the VAD-based regimens are very cost-effective 
according to the WHO recommended thresholds for cost-effectiveness in patients with 
MM in Macao.
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OBJECTIVES: To compare costs and outcomes of surgery techniques [open (OP) 
versus laparoscopic (LAP)] for colon rectal surgery in order to assess the impact on 
costs and clinical outcomes under the private payer perspective in Brazil. METHODS: 
A decision tree and a Markov model were developed according to the Brazilian 
guidelines for Health Technology Assessment (Vianna, 2007). Outcomes rates and 
probabilities for infection, mortality, conversion, survival, recurrence, sepsis and 
hernia were obtained from clinical literature (Gunnarsson 2008, King 2006, Bonjer 
2009, Murray 2006, Brazilian consensus for Sepsis 2003). A panel of specialists was 
conducted to validate the model and capture the local practice. Only direct medical 
costs were considered (Sources: SIMPRO, 2009; CBHPM 5th edition). A lifetime 
perspective was taken and a discount rate of 5% was applied (Vianna, 2007). A 
probabilistic sensitivity analysis was performed to assess the robustness of the results. 
RESULTS: Lengh of staying (LOS) was 9 days for OP versus 6 days for LAP resulting 
in a reduction of hospital costs and medical staff fees (R$5687 OP versus R$4445 
LAP). LAP also reduced the complication costs in 70% (-R$ 981 per procedure). Total 
costs were 8.52% higher for LAP than OP (R$22,085 vs. R$ 20,350), because of 
LAP’s devices costs (R$17,228 vs. R$13,270). In terms of outcomes, due mainly to 
the reduction of infection rate (OP 4.09% vs. 2.11% LAP) and the reduction of sepsis 
cases in 48.41% LAP showed an improvement on overall survival (1.31 years without 
discount and 0.36 years discounted). The sensitivity analysis showed that over 65% 
of the 5000 simulation were cost-effective. 1 USD = R$ 1.78 CONCLUSIONS: Find-
ings suggest LAP as a safer and cost-effective choice for colon cancer surgeries when 
compared with OP.
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OBJECTIVES: To examine the cost-utility of using KRAS mutation testing prior to 
initiating cetuximab monotherapy for patients with metastatic colorectal cancer 
(mCRC) from a US payer perspective. METHODS: A decision analytic model was 
developed to evaluate the clinical and economic impact of three strategies for treating 
mCRC, 1) cetuximab monotherapy; 2) Best supportive care (BSC); and 3) KRAS 
mutation testing with cetuximab for KRAS wild type patients and BSC for patients 
harboring a KRAS mutation. Model parameters were derived from the CO.17 trial, 
published literature, and government sources. The model included trial-based survival 
estimates and adverse event rates as well as costs related to drug treatment and 
administration, KRAS testing, adverse events, and post-progression care. The model 
results were examined using one-way and probabilistic sensitivity analyses. RESULTS: 
Total QALYs for the cetuximab, BSC, and KRAS testing strategies were 0.47, 0.36, 
and 0.47, respectively. Total costs were $44,301; $6,364; and $34,263, respectively. 
Relative to BSC, cetuximab for all and KRAS testing strategies had incremental cost-
effectiveness ratios of $357,224 and $264,644 per QALY, respectively. Relative to 
cetuximab for all, the KRAS testing strategy saved $10,037 with a negligible decrease 
in QALYs. One-way sensitivity analyses found the results to be most sensitive to the 
survival estimates, cost of cetuximab, and the pre progression utility score. In the 
probabilistic sensitivity analysis, BSC had the highest probability of being cost-effec-
tive until a willingness-to-pay of $275,000, after which KRAS testing had the highest 
probability. CONCLUSIONS: These results suggest that the use of KRAS testing to 
select patients for cetuximab treatment in mCRC can reduce costs with a negligible 
impact on QALYs as compared to using cetuximab for all patients. However, the 
cost-effectiveness of KRAS testing vs. best supportive care remains well above com-
monly used cost-effectiveness thresholds.
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OBJECTIVES: Sorafenib improves survival in AHCC (Llovet, NEJM 2008), and has 
been considered cost-effective in Canada (Muszbek, Curr Med Res Opin 2008), when 
compared with BSC. In clinical practice, however, patients with AHCC with no access 
to sorafenib are often treated with other systemic agents, none of which are able to 
improve the outcome. The objective of this study was to evaluate the cost-effectiveness 
of sorafenib+BSC vs BSC alone in Brazil, from the perspective of the private health-
care system. METHODS: A Markov model was developed to project the lifetime 
survival and costs for both interventions using data from the TTP and OS Kaplan-
Meier curves from SHARP trial in a lognormal distribution and from an ad hoc panel 
with Brazilian medical oncologists, hepatologists, and liver surgeons. Treatment effec-
tiveness was measured in life-years gained (LYG). Resource utilization included drug, 
administration, physician visits, monitoring, and adverse events. Costs (in R$, with 
R$ 1.00 ∼ US$ 0.58) and survival beneﬁts were discounted annually at 5%. Univariate 
and probabilistic sensitivity analyses were conducted. RESULTS: Lifetime per-patient 
costs in R$ (US$) were 103,210 (58,977) and 10,435 (5,963) for sorafenib+BSC and 
BSC alone, respectively. Sorafenib drug cost accounted for nearly 80% of treatment 
costs. The incremental survival beneﬁt with sorafenib+BSC was 0.49 life-years. The 
incremental cost-effectiveness ratio of sorafenib+BSC vs BSC alone was R$ 189,402 
(US$ 108,230) per LYG. CONCLUSIONS: The addition of sorafenib to BSC is the 
only intervention that has been found to improve survival in AHCC and the cost-
effectiveness results reﬂects the increased cost of an active treatment when compared 
with a low cost and ineffective alternative.
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OBJECTIVES: Number of studies shown beneﬁcial effect of granulocyte colony-
stimulating factors (G-CSF) on neutropenia duration in children receiving chemo-
therapy for leukemia. The aim of present analysis was to assess cost-effectiveness of 
lenograstim in comparison with ﬁlgrastim in Polish settings (threshold is about 
100,095 PLN). METHODS: Analysis covered time horizon of one chemotherapy 
cycle. A public payer perspective was adopted for cost analysis. The costs included 
were based on Polish NHF reference costs list. Data on time to ANC recovery, number 
of days with fever, length of hospital stay and antibiotics use were obtained from 
randomized controlled trials (RCTs) identiﬁed in the conducted systematic review. 
These included trials on prophylactic G-CSF use as well as trials in which only patients 
with neutropenia were included. Equations describing costs and QALY according to 
neutropenia and fever length, hospital stay and antibiotic use were established. 
RESULTS: Estimated QALY difference between lenograstim and ﬁlgrastim is 0.0011 
(CI95%[0.0006; 0.0016]). Total costs difference between lenograstim and ﬁlgrastim is 
−533 PLN (CI95%[−1,052; −28]) Probability of lenograstim being cost-effective over 
ﬁlgrastim is 99.16%. Taking into account only trials where G-CSFs were used in 
neutropenia prophylaxis estimated QALY difference between lenograstim and ﬁlgras-
tim is 0.0014 (CI95%[0.0008; 0.0020]). Total costs difference between lenograstim and 
ﬁlgrastim is −699 PLN (CI95%[−1,376; −32]). Probability of lenograstim being cost-
effective over ﬁlgrastim is 98.98%. CONCLUSIONS: Lenograstim is dominant over 
ﬁlgrastim. Acknowledgements: This analysis was supported by Sanoﬁ-Aventis.
PCN70
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THE GRANULOCYTE-COLONY STIMULATING FACTOR (GCSF) IN 
PREPARATION FOR AN AUTOLOGOUS HEMATOPOIETIC STEM CELL 
TRANSPLANTATION ON PATIENTS WITH NON HODGKIN’S 
LYMPHOMA
Salinas G1, Idrovo J2, Zapata L3
1Hospital Infantil de México Federico Gómez, México, DF, Mexico, 2National Institute of 
Public Health, Cuernavaca, Morelos, Mexico, 3Guia Mark, Mexico, DF, Mexico
OBJECTIVES: To estimate the average and incremental cost effectiveness ratios for 
the plerixafor+GCSF treatment, compared to just a GCSF, in preparation for an 
autologous hematopoietic stem cell transplantation on patients with Non Hodgkin’s 
Lymphoma from the institutional perspective in the Mexican context. METHODS: 
Cost-effectiveness analysis by using a decision tree, to compare the costs and results 
of using a Granulocyte-Colony Stimulating Factor vs. GCSF and plerifaxor, from the 
institutional perspective. A 2 year temporal horizon was considered. The effectiveness 
measurement used, took into consideration the percentage of patients that survive the 
transplantation or graft and was obtained from published medicine based clinical 
studies. Only direct medical costs taken from the mexican health system were evalu-
ated. A 5% discount rate was taken into account and a univariated sensitivity analysis 
using relevant variables was summarized in seven scenarios. RESULTS: The GCSF + 
plerixafor treatment demonstrated the least average cost per transplanted patient with 
US$33,291 vs. US$39,768 for treatment with GCSF (1 USD = 13.5MXN) . According 
to the model, effectiveness in relation to the survival of transplanted patients after 2 
